Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem

Autor:	Maria Grazia Ferraro, Marco Bocchetti, Claudia Riccardi, Marco Trifuoggi, Luigi Paduano, Daniela Montesarchio, Gabriella Misso, Rita Santamaria, Marialuisa Piccolo, Carlo Irace
Přispěvatelé:	Ferraro, M. G., Bocchetti, M., Riccardi, C., Trifuoggi, M., Paduano, L., Montesarchio, D., Misso, G., Santamaria, R., Piccolo, M., Irace, C.
Rok vydání:	2023
Předmět:	preclinical investigation DOTAP liposome Organic Chemistry General Medicine triple-negative breast cancer (TNBC) Catalysis nucleolipid nanosystem Computer Science Applications cell migration and invasion Inorganic Chemistry anticancer activity ruthenium(III) complex preclinical investigations Physical and Theoretical Chemistry Molecular Biology Spectroscopy
Zdroj:	International Journal of Molecular Sciences; Volume 24; Issue 7; Pages: 6473
ISSN:	1422-0067
DOI:	10.3390/ijms24076473
Popis:	Based on compelling preclinical evidence concerning the progress of our novel ruthenium-based metallotherapeutics, we are focusing research efforts on challenging indications for the treatment of invasive neoplasms such as the triple-negative breast cancer (TNBC). This malignancy mainly afflicts younger women, who are black, or who have a BRCA1 mutation. Because of faster growing and spreading, TNBC differs from other invasive breast cancers having fewer treatment options and worse prognosis, where existing therapies are mostly ineffective, resulting in a large unmet biomedical need. In this context, we benefited from an experimental model of TNBC both in vitro and in vivo to explore the effects of a biocompatible cationic liposomal nanoformulation, named HoThyRu/DOTAP, able to effectively deliver the antiproliferative ruthenium(III) complex AziRu, thus resulting in a prospective candidate drug. As part of the multitargeting mechanisms featuring metal-based therapeutics other than platinum-containing agents, we herein validate the potential of HoThyRu/DOTAP liposomes to act as a multimodal anticancer agent through inhibition of TNBC cell growth and proliferation, as well as migration and invasion. The here-obtained preclinical findings suggest a potential targeting of the complex pathways network controlling invasive and migratory cancer phenotypes. Overall, in the field of alternative chemotherapy to platinum-based drugs, these outcomes suggest prospective brand-new settings for the nanostructured AziRu complex to get promising goals for the treatment of metastatic TNBC.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e86ff29a4e890c80a38bf56406c97f8b https://doi.org/10.3390/ijms24076473 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.